EGFR-TKI治疗时机对晚期肺腺癌患者总生存的影响

摘要

目的:探索不同时机应用EGFR-TKI(一线治疗VS二/三线治疗)对晚期肺腺癌患者总生存的影响.方法:回顾性分析V期肺腺癌患者的临床资料.比较一线治疗组与二/三线治疗组的临床基线特征、近期疗效等方面的差异.结果:EGFR-TKI二/三线治疗组的总生存时间显著优于一线治疗组,在其它方面无显著差异.结论:EGFR-TKI二/三线治疗可能要优于一线治疗.%Objective: To explore the effect of different tim of EGFR - TKI treatment (first - line vs second - or third - line therapy) on overall survival of patients with advanced lung adenocarcinoma. Methods: Retrospective analysis Clinical data of stage IV lung cancer patients was retropectively analyzed. Results: For EGFR - TKI two / third -line treatment group, overall survival was significantly better than the first - line treatment group, in other aspects there was no significant differences. Conclusion: Second - or third - line EGFR - TKI treatment may be superior to first - line EGFR - TKI.